Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis
The British Journal of Psychiatry · 2026-04 · 228 (4) · 348-356
DOI: 10.1192/bjp.2025.89 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The British Journal of Psychiatry, online erschienen am 02.06.2025. Verfasst von Elias Wagner und 12 weiteren Autor:innen. Beteiligte Einrichtung: Evidence-based Psychiatry and Psychotherapy, Faculty of Medicine, University of Augsburg, Augsburg, Germany. Hauptthemen laut MEDLINE: Antipsychotic Agents, Clozapine, Myocarditis, Schizophrenia, Treatment-Resistant. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Clozapine is the antipsychotic of choice for people with treatment-resistant schizophrenia (TRS) but is associated with the uncommon but potentially life-threatening adverse effect of myocarditis. However, there are no criteria for diagnosing clozapine-associated myocarditis (CAM) or global guidelines on detection and risk reduction, or for restarting clozapine after CAM.
Aims
To develop criteria for CAM and algorithms for clozapine initiation and clozapine rechallenge after CAM in a multiprofessional consensus process.
Method
We conducted a systematic literature search for cases of clozapine rechallenge following CAM using the PubMed, EMBASE, CINAHL and PsycINFO databases, followed by a multidisciplinary international two-step Delphi consensus process in July and October 2024. The Delphi panel comprised psychiatrists, cardiologists, pharmacists, psychopharmacologists and nurses with expertise on clozapine or myocarditis.
Results
Ninety-three clinicians and academics with experience in prescribing clozapine from six continents participated in the Delphi process. A consensus was reached on a definition of CAM according to modified clinical criteria from the European Society of Cardiology for myocarditis associated with immune checkpoint inhibitors. Titration schemes slower than those given in the Summary of Product Characteristics for clozapine were recommended to minimise CAM risk. Minimum and enhanced requirements for screening and monitoring were developed to account for global perspectives and limited resources in certain healthcare systems, and an approach to clozapine rechallenge was elaborated.
Conclusions
This multidisciplinary project represents the first guidance for CAM and will inform clinicians, other caregivers and patients, as well as facilitating the development of national guidelines on CAM prevention, screening and monitoring and rechallenge after an index episode of myocarditis in individuals taking clozapine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Evidence-based Psychiatry and Psychotherapy, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
- Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, BKH Augsburg, Augsburg, Germany.
- Queensland Centre for Mental Health Research, Brisbane, Australia.
- Metro South Addiction and Mental Health Service, Metro South Health, Brisbane, Australia.
- University of Queensland School of Clinical Medicine, Brisbane, Australia.
- Department of Psychiatry and Ottawa Hospital Research Institute Clinical Epidemiology Program, University of Ottawa, Ottawa, Canada.
ORCID-Profile: Elias Wagner, Marco Solmi, Dan Siskind, Oliver D Howes
Zitieren
APA
Wagner, E., Korman, N., Solmi, M., Mortazavi, M., Aminifarsani, Z., Dubrovin Leão, D., Burrage, M. K., Siskind, D., McMahon, L., Howes, O. D., Correll, C. U., CAM Expert Group, & Hasan, A. (2026). Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis. The British Journal of Psychiatry, 228(4), 348-356. https://doi.org/10.1192/bjp.2025.89
Vancouver
Wagner E, Korman N, Solmi M, Mortazavi M, Aminifarsani Z, Dubrovin Leão D, et al. Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis. The British Journal of Psychiatry. 2026;228(4):348-356. doi:10.1192/bjp.2025.89
BibTeX
@article{Wagner2026,
author = {Wagner, Elias and Korman, Nicole and Solmi, Marco and Mortazavi, Matin and Aminifarsani, Zahra and Dubrovin Leão, Douglas and Burrage, Matthew K and Siskind, Dan and McMahon, Laura and Howes, Oliver D and Correll, Christoph U and CAM Expert Group, CAM Expert Group and Hasan, Alkomiet},
title = {Multidisciplinary consensus on prevention, screening and monitoring of clozapine-associated myocarditis and clozapine rechallenge after myocarditis},
journal = {The British Journal of Psychiatry},
year = {2026},
volume = {228},
number = {4},
pages = {348--356},
doi = {10.1192/bjp.2025.89}
}
EUVIMED